Duke Human Vaccine Institute (DHVI)
Medical Research And Development
Why pick this one
Duke Human Vaccine Institute develops vaccines, therapeutics, and diagnostics for HIV-1, influenza, SARS-CoV-2, tuberculosis, and other infections.
Best for
- HIV-1 vaccine research
- Early-phase vaccine development using Good Manufacturing Practice facilities
- Translational research for infectious-disease vaccines, therapeutics, or diagnostics
- Research involving virology, immunology, molecular biology, microbiology, or animal models
- Scientific training in vaccine and biologics development
Look elsewhere if
- Routine patient vaccination or general medical care
- Commercial services unrelated to infectious-disease research and development
Specialties
- HIV-1 vaccine development
- Influenza vaccine research
- SARS-CoV-2 vaccine research
- Tuberculosis vaccine research
- Vaccine, therapeutic, and diagnostic development
- Good Manufacturing Practice production for early-phase vaccine trials
What makes them different
- Established within Duke University in 1990 to develop vaccines and therapeutics for HIV and emerging infections
- Investigator-led discoveries are produced in Good Manufacturing Practice facilities for early-phase vaccine trials
- Research spans HIV-1, influenza, SARS-CoV-2, tuberculosis, syphilis, and gonorrhea
- Interdisciplinary investigators specialize in virology, immunology, molecular biology, microbiology, and animal models
- Leadership role in the Global HIV/AIDS Vaccine Enterprise and emerging-infection and biodefense research
- Years in business
- 36
Distilled from this business's own website.
Contact & Location
- Address
- 2 Genome Ct, Durham, NC 27710
- Phone
- +19196845384
- Website
- http://dhvi.duke.edu/
Services
- Basic infectious-disease research
- Translational vaccine research
- Clinical research
- Therapeutic development
- Diagnostic development
- Vaccine manufacturing and product development
- Scientific training and mentoring